Company Overview
PRF Technologies Ltd. operates as a clinical stage specialty pharmaceutical company dedicated to the reformulation of established therapeutics, specifically aiming to provide an extended period of post-surgical pain relief within the Israeli market. The firm focuses on developing PRF-110, a viscous clear oil-based solution designed to be instilled directly into the surgical site to manage pain. This business model places the company squarely within the Healthcare sector, specifically under the industry classification of Drug Manufacturers - Specialty & Generic, which implies a focus on developing niche pharmaceutical products rather than mass-market generics. The company's scale is defined by a market capitalization of $1.63M and annual revenue of $17,000, with no available data regarding employee count. These valuation and revenue figures indicate that PRF Technologies Ltd. is a micro-cap entity with minimal current revenue generation, suggesting it is likely in an early-stage development phase where capital is being allocated toward research and product development rather than scaling commercial operations.
Financial Health
The company reports trailing twelve-month revenue of $17,000 against a net income of $-4,838,000 and an EBITDA of $-4,348,000, revealing a significant structural gap where operating expenses substantially exceed all revenue streams. This negative net income indicates that the cost structure is currently dominated by research, development, and administrative expenditures typical of clinical-stage biotechnology firms. Free cash flow stands at $-2,449,250, which signifies a substantial cash outflow required to fund ongoing operations and development activities, thereby limiting immediate financial flexibility for external expansion. The company's profitability metrics are stark, with a gross margin of 0.0%, an operating margin of -16200.0%, and a profit margin of 0.0%, illustrating that the company is not yet generating profit from its sales or operations. Despite the negative earnings, the balance sheet holds $4.14M in cash against only $21,000 in debt, creating a highly conservative liquidity position with minimal leverage. The debt-to-equity ratio is recorded at 0.23, further confirming that the company relies almost entirely on equity financing rather than debt obligations. Liquidity is supported by a current ratio of 1.78, indicating that the company possesses sufficient current assets to cover its short-term liabilities with a comfortable buffer. Return on Equity is reported at -90.4% and Return on Assets at -38.7%, metrics that reveal management is currently generating negative returns on the capital invested, a common characteristic for pre-revenue companies burning cash to reach commercialization milestones.
Valuation Assessment
Valuation multiples for the company reflect its lack of earnings, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -0.17, implying that earnings are currently negative and forward-looking expectations do not yet project positive profitability in the near term. The price-to-book ratio stands at 0.20, indicating that the market values the company at significantly less than its book value, a scenario often seen in distressed or pre-revenue biotech assets where the market discounts intangible development risks. Alternative valuation metrics such as a price-to-sales ratio of 95.81 and an EV/EBITDA of 0.38 suggest that investors are pricing the company based on its potential asset value or future commercialization prospects rather than current earnings power. The stock's recent price volatility is framed by a 52-week high of $17.95 and a 52-week low of $2.08, showing a wide trading range typical of low-liquidity micro-cap stocks. The current price sits significantly below the 52-week high, reflecting the market's cautious stance on the company's near-term commercialization timeline. The beta value is listed as N/A, meaning there is insufficient historical data to calculate the stock's price volatility relative to the broader market, leaving its systematic risk undetermined by standard metrics.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that the company does not yet have a consistent track record of growing sales or earnings to compare against prior periods. The absence of positive earnings growth is inherent to the company's stage, as it is not yet profitable enough to demonstrate a trajectory where earnings grow faster than revenue. Regarding income distribution, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This lack of dividend payments confirms that the company reinvests all available cash, including its $4.14M cash reserves, directly into research and development efforts to advance its clinical stage therapeutics. Consequently, the overall growth and income profile is characterized by a complete reliance on capital appreciation potential and future commercial success rather than current cash distributions or consistent revenue expansion.